ASRT Stock Recent News
ASRT LATEST HEADLINES
Assertio (ASRT) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Assertio Holdings, Inc. has impressive growth rates and an attractive valuation. The company's involvement with an opioid in the past may explain the low valuation.
Recently, Zacks.com users have been paying close attention to Assertio (ASRT). This makes it worthwhile to examine what the stock has in store.
Recently, Zacks.com users have been paying close attention to Assertio (ASRT). This makes it worthwhile to examine what the stock has in store.
Assertio Holdings, Inc. (NASDAQ:ASRT ) Q4 2022 Earnings Conference Call March 8, 2023 4:30 PM ET Company Participants Matt Kreps - Darrow Associates, Investor Relations Dan Peisert - President & Chief Executive Officer Paul Schwichtenberg - Senior Vice President & Chief Financial Officer Conference Call Participants Thomas Flaten - Lake Street Scott Henry - ROTH Capital Hamed Khorsand - BWS Financial Mitra Ramgopal - Sidoti Operator Good afternoon and welcome to the Assertio Holdings' Fourth Quarter and Full Year 2022 Financial Results Conference Call. All participants are now in listen-only mode.
Assertio (ASRT) delivered earnings and revenue surprises of 482.61% and 1.58%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Assertio (ASRT) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Assertio (ASRT) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Assertio (ASRT) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.
Assertio is a truly impressive turnaround story that is now set to grow, mostly through M&A. The crucial ingredient is the digital-only sales model, which puts acquired drugs on a much lower cost basis while maintaining sales.